New gold nanoparticle vaccine aims to outsmart COVID-19 variants

NCT ID NCT07183709

Ongoing ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new type of COVID-19 booster vaccine called PepGNP-COVID19. It uses tiny gold nanoparticles to train the immune system's T cells to recognize and fight the virus. The study involves 60 healthy adults aged 18-64 who will receive one of three doses to check safety and immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PepGNP-COVID19 (a synthetic nanoparticle-based T-cell priming peptide vaccine)
What this could lead to: If successful, this could lead to a COVID-19 booster that provides broader and longer-lasting protection, potentially reducing the need for frequent vaccine updates.
What could go wrong: This is a very early Phase 1 trial with only 60 participants, so safety and immune response are still being tested. It may not prove effective or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

Cincinnati Children's Hospital Medical Center Vaccine Research Center

Cincinnati, Ohio, 45229, United States
George Washington University Medical Faculty Associates

Washington D.C., District of Columbia, 20037-3201, United States
University of Alabama at Birmingham School of Medicine - Infectious Disease

Birmingham, Alabama, 35222, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.